The data obtained from prostate cancer and colorectal cancer models suggest that inhibiting the release of PD-L1 in exosomes could be a promising treatment strategy for overcoming resistance to immune checkpoint inhibitors (Poggio et al., 2019). Here, CD274 is linked to prostate cancer.